GLP-2 vs Glutathione

Binds GLP-2 receptor on intestinal enteroendocrine cells. Promotes enterocyte proliferation and reduces apoptosis, increasing villus height and crypt depth. Strengthens tight junctions and reduces intestinal permeability.

GLP-2 (glucagon-like peptide-2) is a 33-amino-acid endogenous proglucagon-derived peptide secreted by intestinal L-cells in response to nutrient ingestion, functioning as a trophic and protective hormone for the intestinal epithelium with roles in mucosal growth, barrier integrity, and nutrient absorption. GLP-2 signals through a specific receptor (GLP-2R) expressed on intestinal subepithelial myofibroblasts and enteric neurons, promoting enterocyte proliferation while inhibiting apoptosis, reducing intestinal permeability, and modulating gut motility to collectively support intestinal adaptation and absorptive capacity. Clinical evidence for GLP-2 pathway activity is established through teduglutide (Gattex/Revestive), a DPP-IV-resistant GLP-2 analog approved by the FDA in 2012 for short bowel syndrome-associated intestinal failure; Phase 3 trials and long-term follow-up studies demonstrated significant reductions in parenteral nutrition requirements, validating GLP-2 receptor agonism as a viable therapeutic approach. Native GLP-2 itself is not used therapeutically due to a plasma half-life of approximately 7 minutes from rapid DPP-IV degradation; clinical application is exclusively through the stabilized analog teduglutide, which requires a prescription and is indicated specifically for short bowel syndrome — a rare gastrointestinal condition — rather than general wellness or off-label intestinal support.

Master endogenous antioxidant tripeptide; neutralizes ROS, regenerates vitamins C and E, supports phase II liver detoxification, maintains intracellular redox balance

Glutathione (γ-glutamyl-cysteinyl-glycine, GSH) is the most abundant endogenous intracellular antioxidant tripeptide, synthesized from cysteine, glutamate, and glycine in virtually all mammalian cells, where it maintains redox homeostasis by scavenging reactive oxygen species, regenerating oxidized vitamins C and E, and serving as substrate for glutathione peroxidase and glutathione S-transferase detoxification pathways. Cysteine availability is the rate-limiting step in GSH synthesis, and depletion of glutathione is a consistent feature of neurodegenerative conditions including Parkinson's disease substantia nigra, where oxidative stress plays a central role in dopaminergic neuronal injury. A randomized, double-blind pilot trial published in Movement Disorders evaluated intravenous glutathione in Parkinson's disease patients; separately, a pharmacokinetic study established that orally ingested glutathione is not systemically bioavailable — failing to raise plasma or erythrocyte GSH levels — which defines the rationale for parenteral and liposomal delivery formulations. Glutathione is available as a compounded injectable preparation and as an oral dietary supplement, but it has no FDA approval for any clinical indication; IV glutathione is administered off-label in integrative settings with an evidence base insufficient to establish efficacy for any specific condition, and claims regarding its use for general wellness or skin lightening lack rigorous clinical support. IV glutathione therapy: intravenous glutathione is offered at integrative medicine clinics, IV therapy lounges, and some telehealth platforms as part of NAD+ IV drips, wellness protocols, or standalone antioxidant infusions. Common clinical doses studied range from 600 mg to 1,200 mg IV per session. IV administration bypasses the oral bioavailability problem and raises plasma glutathione levels acutely, though the clinical significance of this acute elevation for most wellness endpoints remains unestablished in controlled trials. Glutathione IV drips are frequently paired with NAD+ infusions given overlapping antioxidant and mitochondrial support rationales in integrative clinical practice. Glutathione for skin: glutathione has been studied in clinical settings for its melanin-inhibiting properties — specifically, its ability to shift melanin synthesis from eumelanin (darker) toward phaeomelanin (lighter pigmentation) via tyrosinase pathway inhibition. Several small RCTs from Asian clinical centers have examined IV and oral glutathione for skin lightening, with mixed results; the evidence base is not sufficient for regulatory approval in any jurisdiction, and high-dose IV glutathione for cosmetic pigmentation is controversial from a safety standpoint in medical literature. N-acetylcysteine (NAC) is a glutathione precursor with superior oral bioavailability and its own independent research base; it is often preferred for systemic antioxidant applications. Providers offering IV glutathione as part of wellness protocols are listed in the PeptideBase directory.